{
    "organizations": [],
    "uuid": "11b15952b617e37a6b3bde424479f3446bb6beb1",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-expres2ion-resolves-on-preferentia/brief-expres2ion-resolves-on-preferential-rights-issue-idUSFWN1PB0BY",
    "ord_in_thread": 0,
    "title": "BRIEF-ExpreS2ion Resolves On Preferential Rights Issue",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 16 (Reuters) - EXPRES2ION BIOTECH HOLDING AB :\n* EXPRES2ION RESOLVES ON A PREFERENTIAL RIGHTS ISSUE TO ACCELERATE THE COMPANY‘S DEVELOPMENT\n* ‍PREFERENTIAL RIGHTS ISSUE COMPRISES A MAXIMUM OF 2,400,403 SHARES\n* ‍SUBSCRIPTION PRICE OF 8.00 SEK PER SHARE​ * - ‍UPON FULL SUBSCRIPTION OF RIGHTS ISSUE, CO WILL RAISE ABOUT MSEK 19,203,224 BEFORE ISSUE EXPENSES​\n* ‍SUBSCRIPTION PERIOD: FEBRUARY 8 - 27 2018​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-01-16T15:37:00.000+02:00",
    "crawled": "2018-01-17T19:53:18.008+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "expres2ion",
        "biotech",
        "holding",
        "ab",
        "expres2ion",
        "resolve",
        "preferential",
        "right",
        "issue",
        "accelerate",
        "company",
        "development",
        "right",
        "issue",
        "comprises",
        "maximum",
        "share",
        "price",
        "sek",
        "per",
        "full",
        "subscription",
        "right",
        "issue",
        "co",
        "raise",
        "msek",
        "issue",
        "period",
        "february",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}